ATAI Life Sciences/$ATAI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About ATAI Life Sciences
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.
Ticker
$ATAI
Sector
Primary listing
Industry
Pharmaceuticals
Headquarters
Employees
54
ISIN
NL0015000DX5
Website
ATAI Metrics
BasicAdvanced
$583M
-
-$0.91
1.22
-
Price and volume
Market cap
$583M
Beta
1.22
52-week high
$2.99
52-week low
$1.03
Average daily volume
4.8M
Financial strength
Current ratio
4.069
Quick ratio
3.498
Long term debt to equity
9.644
Total debt to equity
19.024
Interest coverage (TTM)
-23.60%
Profitability
EBITDA (TTM)
-96.251
Gross margin (TTM)
-481.75%
Net profit margin (TTM)
-7,997.16%
Operating margin (TTM)
-5,198.98%
Effective tax rate (TTM)
0.50%
Revenue per employee (TTM)
$30,000
Management effectiveness
Return on assets (TTM)
-25.53%
Return on equity (TTM)
-79.43%
Valuation
Price to revenue (TTM)
242.847
Price to book
3.61
Price to tangible book (TTM)
3.7
Price to free cash flow (TTM)
-5.74
Free cash flow yield (TTM)
-17.42%
Free cash flow per share (TTM)
-47.91%
Growth
Revenue change (TTM)
572.56%
Earnings per share change (TTM)
327.65%
3-year revenue growth (CAGR)
55.45%
3-year earnings per share growth (CAGR)
-13.49%
What the Analysts think about ATAI
Analyst ratings (Buy, Hold, Sell) for ATAI Life Sciences stock.
Bulls say / Bears say
Positive Phase 2b results for BPL-003 in treatment-resistant depression indicate strong efficacy and safety, potentially leading to regulatory approval and market adoption. (ft.com)
The $50 million private placement financing enhances atai's financial position, supporting ongoing and future clinical trials. (atai.gcs-web.com)
The acquisition of Beckley Psytech for $390 million positions atai as a leader in psychedelic mental health therapies, expanding its pipeline and market reach. (ft.com)
Shares have declined 89% since the 2021 IPO, reflecting investor skepticism and market volatility in the psychedelic drug sector. (ft.com)
The company reported a net loss of $149.3 million in 2024, up from $40.2 million in 2023, indicating increasing financial strain. (stocktitan.net)
Despite promising clinical results, the psychedelic drug sector remains financially volatile, with many companies not yet generating sales, posing risks to atai's financial stability. (ft.com)
Data summarised monthly by Lightyear AI. Last updated on 6 Jul 2025.
ATAI Financial Performance
Revenues and expenses
ATAI Earnings Performance
Company profitability
ATAI News
AllArticlesVideos
atai Life Sciences price target boosted on robust BPL-003 mid-stage trial results
Proactive Investors·6 days ago
Atai and Beckley Psytech hail DMT trial results in treatment-resistant depression
Proactive Investors·6 days ago
Atai Life Sciences And Merger Partner Set Up Psychedelic Depression Therapy With Encouraging Late-Stage Data
Benzinga·1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for ATAI Life Sciences stock?
ATAI Life Sciences (ATAI) has a market cap of $583M as of July 08, 2025.
What is the P/E ratio for ATAI Life Sciences stock?
The price to earnings (P/E) ratio for ATAI Life Sciences (ATAI) stock is 0 as of July 08, 2025.
Does ATAI Life Sciences stock pay dividends?
No, ATAI Life Sciences (ATAI) stock does not pay dividends to its shareholders as of July 08, 2025.
When is the next ATAI Life Sciences dividend payment date?
ATAI Life Sciences (ATAI) stock does not pay dividends to its shareholders.
What is the beta indicator for ATAI Life Sciences?
ATAI Life Sciences (ATAI) has a beta rating of 1.22. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.